In the case of United States v. Walsh, Trading as Kelp Laboratories (1946), the U.S Supreme Court ruled in favor of the government, upholding a lower court's decision that certain products sold by Kelp Laboratories were misbranded under the Federal Food, Drug and Cosmetic Act. The company had been selling tablets containing iodine derived from kelp with labels claiming they could prevent goiter and stimulate thyroid function without any scientific evidence to support these claims. The court found this to be misleading for consumers who might rely on such information when making health decisions. This ruling reinforced federal authority over labeling standards for food and drug products, emphasizing that manufacturers must have substantial proof before making health-related claims about their products.

In the dissenting opinion for United States v. Walsh, Trading as Kelp Laboratories, Justice Frankfurter argued that the majority's decision to uphold a conviction under the Federal Food, Drug and Cosmetic Act was too broad in its interpretation of "misbranding." He contended that while it is important to protect consumers from misleading labels or false claims about a product's benefits, this should not extend to punishing manufacturers who make truthful statements about their products' ingredients. In his view, if all information on a label is factually accurate but could potentially be misinterpreted by some consumers due to lack of scientific knowledge or understanding - as was claimed in this case regarding kelp tablets labeled with iodine content - then responsibility lies more with public education than legal punishment for manufacturers. Furthermore, he expressed concern over potential chilling effects on free speech and commerce resulting from overly punitive interpretations of regulatory laws.